Skip to main content

Main menu

  • Home
  • Current Issue
  • Ahead of Print
  • Past Issues
  • Info for
    • Authors
    • Print Subscriptions
  • About
    • About the Journal
    • About the Academy
    • Editorial Board
  • Feedback
  • Alerts
  • AAPL

User menu

  • Alerts

Search

  • Advanced search
Journal of the American Academy of Psychiatry and the Law
  • AAPL
  • Alerts
Journal of the American Academy of Psychiatry and the Law

Advanced Search

  • Home
  • Current Issue
  • Ahead of Print
  • Past Issues
  • Info for
    • Authors
    • Print Subscriptions
  • About
    • About the Journal
    • About the Academy
    • Editorial Board
  • Feedback
  • Alerts
LetterLETTERS
Ahmad Ghanizadeh and Shahin Akhondzadeh
Journal of the American Academy of Psychiatry and the Law Online June 2009, 37 (2) 278;
Ahmad Ghanizadeh
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahin Akhondzadeh
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Editor:

We thank Kenneth Appelbaum for his interesting article, “Attention Deficit Hyperactivity Disorder in Prison: A Treatment Protocol”,1 published in The Journal earlier this year.

One of the subjects discussed was the criteria for the treatment with stimulants of prison inmates with attention-deficit hyperactivity disorder (ADHD). At first, nonpharmacological treatment recommendations were provided. Appelbaum explained that atomoxetine had not been added to the statewide formulary when the protocol was developed. Then, he expressed his concerns about treating inmates with controlled substances such as stimulants. The protocol proposes that stimulants be recommended only after the failure of a complete trial of one or more nonstimulant medications, or when such trials are contraindicated, and after a review of the patient's substance abuse history. The protocol then recommends prescription of immediate-release medications that decrease the risk of misuse. It also requires documentation of objective improvement in functioning. In the case of stimulant misuse by an inmate, the medication is stopped.1

Kathryn Burns’ interesting commentary reminded us of the limitations that should be placed on the prescription of controlled substances in prisons. She recommended that prescriptions be restricted because of the high prevalence of substance use disorders in prison populations, the potential for misuse, the barter and sale of controlled substances among inmates, challenges for nursing, direct and indirect costs, and available alternatives.2

Burns was correct in stating that there are some important concerns that should be discussed. However, it seems that at least some of them were included in Appelbaum's protocol. Moreover, if the prescribing of medication for inmates, in light of Appelbaum's criteria, is discouraged, the question should be raised as to whether, despite the need to control such medications, it is ethical to deprive inmates of well-known and effective treatment just because there are risks. It should be noted that ADHD may be a risk factor for the inmates’ imprisonment. Perhaps, future studies to investigate the possible risks, costs, and benefits of prescribing stimulants for inmates are needed.

  • American Academy of Psychiatry and the Law

References

  1. ↵
    Appelbaum KL: Attention deficit hyperactivity disorder in prison: a treatment protocol. J Am Acad Psychiatry Law 37:45–9, 2009
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Burns KA: Commentary: the top ten reasons to limit prescription of controlled substances in prisons. J Am Acad Psychiatry Law 37:50–2, 2009
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Academy of Psychiatry and the Law Online: 37 (2)
Journal of the American Academy of Psychiatry and the Law Online
Vol. 37, Issue 2
June 2009
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in recommending The Journal of the American Academy of Psychiatry and the Law site.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
(Your Name) has forwarded a page to you from Journal of the American Academy of Psychiatry and the Law
(Your Name) thought you would like to see this page from the Journal of the American Academy of Psychiatry and the Law web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Ahmad Ghanizadeh, Shahin Akhondzadeh
Journal of the American Academy of Psychiatry and the Law Online Jun 2009, 37 (2) 278;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Ahmad Ghanizadeh, Shahin Akhondzadeh
Journal of the American Academy of Psychiatry and the Law Online Jun 2009, 37 (2) 278;
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Letters
  • Letters
  • Letters
Show more Letters

Similar Articles

Site Navigation

  • Home
  • Current Issue
  • Ahead of Print
  • Archive
  • Information for Authors
  • About the Journal
  • Editorial Board
  • Feedback
  • Alerts

Other Resources

  • Academy Website
  • AAPL Meetings
  • AAPL Annual Review Course

Reviewers

  • Peer Reviewers

Other Publications

  • AAPL Practice Guidelines
  • AAPL Newsletter
  • AAPL Ethics Guidelines
  • AAPL Amicus Briefs
  • Landmark Cases

Customer Service

  • Cookie Policy
  • Reprints and Permissions
  • Order Physical Copy

Copyright © 2025 by The American Academy of Psychiatry and the Law